Biosafety assays for the diagnosis and prediction of drug-related complement pathology

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 952520

Biological therapies and vaccines: safety issues, physiological and immunological mechanisms

Summer School for PhD students and young researchers

15-16. 06. 2021.

online

The aim of this two-day summer school is to provide a practical, hands-on experience of biosafety issues beyond the university level. The language of Summer School will be English.

Registration:

kotnyek.orsolya@semmelweis-univ.hu

More information about the Biosafety project and registration:

https://semmelweis.hu/biosafety/

## Program

**June 15, 2021**

9:00 Orsolya Kotnyek (*Project coordinator*)
Nadja Prang, TecoBiosciences GmbH, Landshut, Germany
**Introduction of the project**

9:15 János Szebeni (*project leader*)
Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
**Hypersensitivity to Nano-biopharmaceuticals and COVID vaccines**

10:00 Nadja Prang
TecoBiosciences GmbH, Landshut, Germany
**Biosafety markers**

10:45-11:00 break

Semmelweis Egyetem
**„Az orvos-, egészségtudományi és gyógyszerészképzés tudományos műhelyeinek fejlesztése"** című,
**EFOP-3.6.3-VEKOP-16-2017-00009** azonosítószámú projekt

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 952520

11:00 László Dézsi
Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
**Animal models of complement activation-related hypersensitivity**

11:45 Gaston Fuentes Estevez
Translational Nanobiomaterials and Imaging
Leiden University Medical Center, Leiden, The Netherlands
**Biosafety of Nanobiomaterials**

12:30 13:45 break

13:45 Karolina Pircs
Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
**Direct neural conversion: New possibilities to model late onset neurodegenerative diseases**

14:30 Zoltán Benyó
Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
**Molecular mechanisms of niacin-induced flushing**

15:15 Miklós Kellermayer
Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
**Biophysical virology of SARS-CoV-2**

**June 16, 2021**

9:00 Marina A. Dobrovolskaia
Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick MD, USA
**Preclinical immunological characterization of nanoparticles**

9:45 Tamás Fülöp
Tecodevelopment GmbH, Rheinbach, Germany
**Complement immunoassay development for biosafety research**

10:30-10:45 break

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 952520

10:45 Gábor Szénási
Institute of Translational Medicine Semmelweis University, Budapest, Hungary
**Murine models of liposome reactions: technical challenges and mechanisms**

11.30 Daan J.A. Crommelin
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
**Pharmaceutical aspects of biologicals/vaccines: characterization, critical quality attributes, stability**

12:15 Ákos Koller
Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
New York Medical College, NY, USA
**Nitric oxide: a basic science hero, but what about safety and therapy?**

13:00-15:00 break

15:00 Exam